GB202006629D0 - Specific binding molecules - Google Patents

Specific binding molecules

Info

Publication number
GB202006629D0
GB202006629D0 GBGB2006629.6A GB202006629A GB202006629D0 GB 202006629 D0 GB202006629 D0 GB 202006629D0 GB 202006629 A GB202006629 A GB 202006629A GB 202006629 D0 GB202006629 D0 GB 202006629D0
Authority
GB
United Kingdom
Prior art keywords
specific binding
binding molecules
molecules
specific
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2006629.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunocore Ltd
Original Assignee
Immunocore Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunocore Ltd filed Critical Immunocore Ltd
Priority to GBGB2006629.6A priority Critical patent/GB202006629D0/en
Publication of GB202006629D0 publication Critical patent/GB202006629D0/en
Priority to CN202180042266.0A priority patent/CN115867310A/zh
Priority to JP2022567414A priority patent/JP7682927B2/ja
Priority to PCT/EP2021/061731 priority patent/WO2021224261A1/en
Priority to EP21723720.5A priority patent/EP4146257A1/en
Priority to US17/998,032 priority patent/US20230348595A1/en
Priority to CA3181362A priority patent/CA3181362A1/en
Priority to AU2021267361A priority patent/AU2021267361A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
GBGB2006629.6A 2020-05-05 2020-05-05 Specific binding molecules Ceased GB202006629D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB2006629.6A GB202006629D0 (en) 2020-05-05 2020-05-05 Specific binding molecules
CN202180042266.0A CN115867310A (zh) 2020-05-05 2021-05-04 用于治疗癌症的识别kras g12d的抗cd3的可溶性tors和融合物
JP2022567414A JP7682927B2 (ja) 2020-05-05 2021-05-04 特異的結合性分子
PCT/EP2021/061731 WO2021224261A1 (en) 2020-05-05 2021-05-04 Soluble tors and fusions to anti-cd3 recognising kras g12d for the treatment of cancer
EP21723720.5A EP4146257A1 (en) 2020-05-05 2021-05-04 Soluble tors and fusions to anti-cd3 recognising kras g12d for the treatment of cancer
US17/998,032 US20230348595A1 (en) 2020-05-05 2021-05-04 Soluble tcrs and fusions to anti-cd3 recognizing kras g12d for the treatment of cancer
CA3181362A CA3181362A1 (en) 2020-05-05 2021-05-04 Soluble tors and fusions to anti-cd3 recognising kras g12d for the treatment of cancer
AU2021267361A AU2021267361A1 (en) 2020-05-05 2021-05-04 Soluble tors and fusions to anti-CD3 recognising kras G12D for the treatment of cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2006629.6A GB202006629D0 (en) 2020-05-05 2020-05-05 Specific binding molecules

Publications (1)

Publication Number Publication Date
GB202006629D0 true GB202006629D0 (en) 2020-06-17

Family

ID=71080372

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2006629.6A Ceased GB202006629D0 (en) 2020-05-05 2020-05-05 Specific binding molecules

Country Status (8)

Country Link
US (1) US20230348595A1 (https=)
EP (1) EP4146257A1 (https=)
JP (1) JP7682927B2 (https=)
CN (1) CN115867310A (https=)
AU (1) AU2021267361A1 (https=)
CA (1) CA3181362A1 (https=)
GB (1) GB202006629D0 (https=)
WO (1) WO2021224261A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201901305D0 (en) * 2019-01-30 2019-03-20 Immunocore Ltd Specific binding molecules
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
CN115850444B (zh) * 2022-09-15 2025-01-28 重庆医科大学 Tcr或其抗原结合片段及其应用
CN118812698A (zh) * 2023-04-19 2024-10-22 香雪生命科学技术（广东）有限公司 一种识别kras突变的高亲和力t细胞受体及其应用
CN118852403A (zh) * 2023-04-26 2024-10-29 北京鼎成肽源生物技术有限公司 靶向kras突变的tcr分子和细胞及其应用
CN118852452A (zh) * 2023-04-28 2024-10-29 北京鼎成肽源生物技术有限公司 靶向kras g12突变的tcr分子和细胞及其应用
CN120157754A (zh) * 2023-12-14 2025-06-17 新景智源生物科技(苏州)有限公司 Kras_g12d突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞
WO2025189363A1 (zh) * 2024-03-12 2025-09-18 广州医科大学 一种t细胞受体(tcr)及其用途
CN120647748B (zh) * 2025-05-16 2026-03-06 浙江大学 一种活性提升的tcr及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039482A1 (en) 1997-03-07 1998-09-11 Sunol Molecular Corporation Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor
ATE533784T1 (de) 1997-10-02 2011-12-15 Altor Bioscience Corp Lösliche, einzelkettige proteine des t- zellrezeptors
MXPA02005559A (es) 1999-12-06 2004-09-10 Univ Illinois Proteinas de tcr de alta afinidad y metodos.
EP1259601A2 (en) 2000-02-22 2002-11-27 Ahuva Nissim Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof
IL160359A0 (en) 2001-08-31 2004-07-25 Avidex Ltd Soluble t cell receptor
CA2501870C (en) 2002-10-09 2013-07-02 Avidex Limited Single chain recombinant t cell receptors
PT1558643E (pt) 2002-11-09 2009-08-24 Immunocore Ltd Apresentação de um receptor das células t
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
GB201314404D0 (en) * 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
US11827688B2 (en) 2016-06-02 2023-11-28 Immunocore Limited Dosing regimen for GP100-specific TCR—anti-CD3 SCFV fusion protein
LT3428194T (lt) 2017-07-14 2021-12-10 Immatics Biotechnologies Gmbh Pagerinta dvejopo savitumo polipeptido molekulė

Also Published As

Publication number Publication date
EP4146257A1 (en) 2023-03-15
JP2023524788A (ja) 2023-06-13
CN115867310A (zh) 2023-03-28
WO2021224261A1 (en) 2021-11-11
AU2021267361A1 (en) 2022-12-15
JP7682927B2 (ja) 2025-05-26
US20230348595A1 (en) 2023-11-02
CA3181362A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
GB202006629D0 (en) Specific binding molecules
GB201901306D0 (en) Multi-domain binding molecules
GB201901305D0 (en) Specific binding molecules
IL289867A (en) Immunostimulatory multisegmented binding compounds
IL289415A (en) Claudin-6 binding molecules and their use
IL288314A (en) Anti-tdp-43 binding molecules and uses thereof
GB201811408D0 (en) CD137 Binding Molecules
GB202020154D0 (en) ROR1-specific variant antigen binding molecules
GB201915282D0 (en) Specific binding molecules
IL287555A (en) binding compounds
GB201702091D0 (en) Specific binding molecules
IL288561A (en) gal9-binding molecules with immunosuppressive activity
SG11202109535SA (en) Cd3 binding molecules
GB202010329D0 (en) Specific binding molecules
GB202306345D0 (en) Binding molecules
GB201906118D0 (en) Anti-LAG-3 binding molecules
IL318933A (en) Multi-functional binding molecules
IL318930A (en) Multi-functional binding molecules
GB201803178D0 (en) Specific binding molecules for htert
GB201904328D0 (en) Specific binding molecules
EP3976199A4 (en) ACTIVATION OF ANTI-GAL9 ANTIBODY BINDING MOLECULES
GB202210680D0 (en) Binding molecules targeting il-35r
GB202110360D0 (en) Binding molecules
GB202100737D0 (en) Binding molecules
GB202016611D0 (en) Binding molecules

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)